A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Unless we state otherwise or the context otherwise requires, references in this Annual Report on Form 10-K to “we,” “our,” “us,” “ZIVO,” “the Registrant” or “the Company” refer to Zivo Bioscience, Inc., a Nevada corporation, and its subsidiaries. We are a research and development company operating in both the biotech and agtech sectors, with an intellectual property portfolio comprised of proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. We believe that our proprietary algal culture and materials derived therefrom show promise in benefiting both animal and human health, primarily through inflammation-modulating and immune-boosting properties.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | 0 | 0 | - |
| Net Income | -20M | -13M | -7.8M | -8.7M | -8.8M | -9.1M |
| EPS | $-6.05 | $-4.23 | $-4.60 | $-5.57 | $-6.90 | $-5.80 |
| Free Cash Flow | 0 | -4.3M | -5.8M | -7.1M | -6.8M | -2.6M |
| ROIC | -1194.1% | -642.4% | -1032.5% | -324.9% | -113.0% | -3069.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -4.19 | -1.25 | -200.87 | 0.49 | -0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -8.5M | -13M | -7.3M | -8.7M | -8.6M | -8.6M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | - | - | -290.0% | -144.9% | - |
| Shares Outstanding | 4M | 3M | 2M | 2M | 1M | 2M |
Zivo Bioscience, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Zivo Bioscience, Inc. (ZIVO) has a 5-year average return on invested capital (ROIC) of -113.0%. This is below average and may indicate limited pricing power.
Zivo Bioscience, Inc. (ZIVO) has a market capitalization of $9M. It is classified as a small-cap stock.
Zivo Bioscience, Inc. (ZIVO) does not currently pay a regular dividend.
Zivo Bioscience, Inc. (ZIVO) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Zivo Bioscience, Inc. (ZIVO) generated $-4 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Zivo Bioscience, Inc. (ZIVO) reported earnings per share (EPS) of $-4.23 in its most recent fiscal year.
The Ledger Terminal provides 15 years of financial data for Zivo Bioscience, Inc. (ZIVO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Zivo Bioscience, Inc. (ZIVO) has a book value per share of $-0.16, based on its most recent annual SEC filing.